Predictive Oncology Inc. (NASDAQ: POAI) has priced two concurrent private placement transactions totaling approximately $344.4 million, the company announced. The move is designed to support a new digital asset treasury strategy focused on accumulating ATH, the native utility token of the Aethir ecosystem.
The financing consists of a $51.7 million cash PIPE and a $292.7 million crypto PIPE involving pre-funded warrants. Proceeds from the offerings are earmarked for the acquisition of ATH tokens, working capital, and general corporate purposes. The company stated that the strategy aligns with its broader vision to leverage emerging technologies.
Predictive Oncology specializes in using artificial intelligence and machine learning to expedite early drug discovery for cancer treatments. Its proprietary AI platform, PEDAL, can predict with 92% accuracy whether a tumor sample will respond to a specific drug compound. The company also maintains a biobank of over 150,000 assay-capable human tumor samples, offering one of the industry's broadest AI-based drug discovery solutions. Headquartered in Pittsburgh, Pennsylvania, Predictive Oncology operates a wholly owned CLIA laboratory facility.
The decision to adopt a digital asset treasury strategy marks a significant shift for the company, which has traditionally focused on biotechnology. By accumulating ATH tokens, Predictive Oncology is positioning itself to participate in the Aethir ecosystem, though specific details on how this will integrate with its core business have not been disclosed. The company emphasized that the strategy is intended to enhance shareholder value and provide exposure to the growing digital asset space.
For more information about Predictive Oncology, visit https://predictive-oncology.com/. The full press release can be accessed at https://ccw.fm/oIn6g.
